Table 1.

Clinical data for patients with SMARCA4-UT on the therapy of immunotherapy.

	No.	Age(Y)/gender	Smoking status	Lesion location	TMN	PD-L1 TPS (%)	TMB (/Mb)	Mutation	Treatment	Outcome (follow-up)
Henon et al. (4)	1	58/F	Unknown	Mediastinal, hilar and paratracheal involvement, along with pleural and peritoneal metastases	IV	0	Remarkably low	Unknown	Radiotherapy+ chemotherapy+ pembrolizumab	11 months PR to March 2019
Kunimass et al. (5)	2	51/M	22.5 pack-years	Right lung upper lobe with soft tissue, vertebral invasion and pleural	IVA	0	10.2	SMARCA4(L1161fs), TP53 (V157L)	ABCP + surgery	9 months PR after surgery to August 2021
Kohichi et al. (6)	3	69/F	Unknown	Left mediastinal tumor, peritoneal and retroperitoneal dissemination and multiple cutaneous metastases	IV	60	Unknown	Unknown	Pembrolizumab	8 cycles of PR to September 2019
Kawachi et al. (7)	4	73/F	53 pack-years	Left upper lobe, mediastinal lymphadenopathy and osteolytic metastasis in the fifth cervical vertebra	IVB	40	11	SMARCA4(c.1119-1G>T), TP53, SPTA1, CHD2	ABCP	Progressed after 17 months of PR to 2021
Kawachi et al. (7)	5	59/M	39 pack-years	Left lower lobe, an oropharyngeal mass, left adrenal gland mass, left cervical lymphadenopathy, left hilar lymphadenopathy and multiple abdominal lymphadenopathies	IVB	0	11.8	SMARCA4(K755Nfs), TP53, TSC2	ABCP	Progressed after 10 months of PR to 2021
Kawachi et al. (7)	6	64/F	44 pack-years	Left upper lung lobe, mediastinal lymphadenopathy and a brain mass in the left parietal lobe	IVB	80	14.9	SMARCA4(H103Mfs), TP53,SPTA1,TSC2, KEAP1	ABCP+ Radiotherapy	Progressed after 7 cycles of PR and 2 months maintenance therapy to 2021
Anžiča et al. (8)	7	41/M	Current smoker	Upper anterior mediastinum encompassing infracarinal and hilar lymph nodes.	IV	100	674SNV and 47 indels	CDKN2A(p.T18fs), SMARCA4(p.K1334fs)	Pembrolizumab + ipilimumab + chemotherapy + radiotherapy	25 months to death

ABCP, atezolizumab, bevacizumab, paclitaxel, and carboplatins.